4.4 Article

Menopause Is a Determinant of Breast Adipose Inflammation

期刊

CANCER PREVENTION RESEARCH
卷 8, 期 5, 页码 349-358

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1940-6207.CAPR-14-0243

关键词

-

类别

资金

  1. NIH/NCI [R01CA154481]
  2. Clinical and Translational Science Center at Weill Cornell Medical College [UL1TR000457]
  3. Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) Young Investigator Award
  4. Royal Academy of Medicine in Ireland
  5. St. Luke's Young Investigator Award
  6. Expedition Inspiration Young Investigator Award
  7. Botwinick-Wolfensohn Foundation
  8. Breast Cancer Research Foundation

向作者/读者索取更多资源

Chronic inflammation is recognized as a risk factor for the development of several malignancies. Local white adipose tissue (WAT) inflammation, defined by the presence of dead or dying adipocytes encircled by macrophages that form crown-like structures (CLS), occurs in the breasts (CLS-B) of most overweight and obese women. Previously, we showed that the presence of CLS-B is associated with elevated tissue levels of proinflammatory mediators and aromatase, the rate-limiting enzyme for estrogen biosynthesis. The associated increased levels of aromatase in the breast provide a plausible mechanistic link between WAT inflammation and estrogen-dependent breast cancers. Thus, breast WAT inflammation could be relevant for explaining the high incidence of estrogen-dependent tumors with aging despite diminished circulating estrogen levels after menopause. To explore this possibility, we determined whether menopause in addition to body mass index (BMI) is associated with breast WAT inflammation among 237 prospectively enrolled women. The presence of CLS-B and its severity (CLS-B/cm(2)) as indicators of WAT inflammation correlated with menopausal status (P = 0.008 and P < 0.001) and BMI (P < 0.001 for both). In multivariable analyses adjusted for BMI, the postmenopausal state was independently associated with the presence (P = 0.03) and severity of breast WAT inflammation (P = 0.01). Mean adipocyte size increased in association with CLS-B (P < 0.001). Our findings demonstrate that breast WAT inflammation, which is associated with elevated aromatase levels, is increased in association with the postmenopausal state independent of BMI. Breast WAT inflammation, a process that can potentially be targeted, may help to explain the high incidence of estrogen-dependent tumors in postmenopausal women. (C) 2015 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Retraction Biochemistry & Molecular Biology

撤稿声明: Withdrawal: Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription (Retraction of Vol 283, Pg 33955, 2008)

Kotha Subbaramaiah, Robert Benezra, Clifford Hudis, Andrew J. Dannenberg

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Retraction Biochemistry & Molecular Biology

撤稿声明: Withdrawal: EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells: Evidence of a BRCA1 and p300 exchange (Retraction of Vol 283, Pg 33955, 2008)

Kotha Subbaramaiah, Clifford Hudis, Sung-Hee Chang, Timothy Hla, Andrew J. Dannenberg

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Article Oncology

Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies

Elizabeth Garrett-Mayer, Melinda W. Kaltenbaugh, Rebecca Spence, Suanna S. Bruinooge, Clifford A. Hudis, Dina Michels, Richard L. Schilsky

JOURNAL OF CLINICAL ONCOLOGY (2020)

Article Oncology

First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

Mark P. S. Dunphy, Christina Pressl, Nagavarakishore Pillarsetty, Milan Grkovski, Shanu Modi, Komal Jhaveri, Larry Norton, Bradley J. Beattie, Pat B. Zanzonico, Danuta Zatorska, Tony Taldone, Stefan O. Ochiana, Mohammad M. Uddin, Eva M. Burnazi, Serge K. Lyashchenko, Clifford A. Hudis, Jacqueline Bromberg, Heiko M. Schoder, Josef J. Fox, Hanwen Zhang, Gabriela Chiosis, Jason S. Lewis, Steven M. Larson

CLINICAL CANCER RESEARCH (2020)

Article Oncology

Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease

Alyssa A. Schatz, Thomas K. Oliver, Robert A. Swarm, Judith A. Paice, Deepika S. Darbari, Deborah Dowell, Salimah H. Meghani, Katy Winckworth-Prejsnar, Eduardo Bruera, Robert M. Plovnick, Lisa Richardson, Neha Vapiwala, Dana Wollins, Clifford A. Hudis, Robert W. Carlson

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)

Article Oncology

Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

Mark Jesus M. Magbanua, Laura H. Hendrix, Terry Hyslop, William T. Barry, Eric P. Winer, Clifford Hudis, Deborah Toppmeyer, Lisa Anne Carey, Ann H. Partridge, Jean-Yves Pierga, Tanja Fehm, Jose Vidal-Martinez, Dimitrios Mavroudis, Jose A. Garcia-Saenz, Justin Stebbing, Paola Gazzaniga, Luis Manso, Rita Zamarchi, Maria Luisa Antelo, Leticia De Mattos-Arruda, Daniele Generali, Carlos Caldas, Elisabetta Munzone, Luc Dirix, Amy L. Delson, Harold J. Burstein, Misbah Qadir, Cynthia Ma, Janet H. Scott, Francois-Clement Bidard, John W. Park, Hope S. Rugo

Summary: This study identified 4 novel prognostic groups in metastatic breast cancer (MBC) based on similarities in circulating tumor cell (CTC) trajectory patterns during chemotherapy. Patients with intermediate+high CTCs (19.4%) had significantly poorer outcomes and may benefit from more effective treatment. This novel prognostic classification approach may guide future prospective clinical trials in MBC.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Retraction Oncology

撤稿声明: Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women (Retraction of Vol 2, Pg 356, 2012)

Kotha Subbaramaiah, Patrick G. Morris, Xi Kathy Zhou, Monica Morrow, Baoheng Du, Dilip Giri, Levy Kopelovich, Clifford A. Hudis, Andrew J. Dannenberg

CANCER DISCOVERY (2021)

Article Oncology

Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance)

Jennifer A. Ligibel, Luke Huebner, Hope S. Rugo, Harold J. Burstein, Debra L. Toppmeyer, Carey K. Anders, Cynthia Ma, William T. Barry, Vera Suman, Lisa A. Carey, Ann H. Partridge, Clifford A. Hudis, Eric P. Winer

Summary: In metastatic breast cancer patients, high rates of obesity and inactivity were observed, but they were not significantly associated with PFS and OS. Greater than 9 MET hours of PA per week may be marginally associated with improved PFS and OS outcomes.

JNCI CANCER SPECTRUM (2021)

Meeting Abstract Oncology

Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)

Cynthia X. Ma, Vera Suman, A. Marilyn Leitch, Souzan Sanati, Kiran Vij, Gary W. Unzeitig, Jeremy Hoog, Mark Watson, Olwen Hahn, Joseph Guenther, Abigail Caudle, Erika Crouch, Horacio Maluf, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J. Hieken, Yang Wang, Travis Dockter, Jo Anne Zujewski, Anna Weiss, Kelly Hunt, Clifford Hudis, Eric P. Winer, Matthew J. Ellis, Lisa A. Carey, Ann H. Partridge

CANCER RESEARCH (2021)

Meeting Abstract Oncology

Validation of a predictive model for potential response to neoadjuvant endocrine therapy ( NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)

Matthew J. Ellis, Vera Suman, A. Marilyn Leitch, Souzan Sanati, Kiran Vij, Gary W. Unzeitig, Jeremy Hoog, Mark Watson, Olwen Hahn, Joseph Guenther, Abigail Caudle, Erika Crouch, Horacio Maluf, Mitch Dowsett, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J. Hieken, Yang Wang, Travis Dockter, Jo Anne Zujewski, Anna Weiss, Clifford Hudis, Eric P. Winer, Kelly Hunt, Ann H. Partridge, Cynthia X. Ma, Lisa A. Carey

CANCER RESEARCH (2021)

Letter Oncology

Reply to M. Hutton-Potts and AM Joshua

Clifford A. Hudis, Richard L. Schilsky

JCO ONCOLOGY PRACTICE (2020)

Article Oncology

Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease

Alyssa A. Schatz, Thomas K. Oliver, Robert A. Swarm, Judith A. Paice, Deepika S. Darbari, Deborah Dowell, Salimah H. Meghani, Katy Winckworth-Prejsnar, Eduardo Bruera, Robert M. Plovnick, Lisa Richardson, Neha Vapiwala, Dana Wollins, Clifford A. Hudis, Robert W. Carlson

JCO ONCOLOGY PRACTICE (2020)

Meeting Abstract Oncology

ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or Ill estrogen receptor-positive HER2-negative breast cancer (ER+HER2-BC) in postmenopausal (PM) women: Alliance A011106.

Cynthia X. Ma, Vera J. Suman, A. Marilyn Leitch, Souzan Sanati, Kiran R. Vij, Gary Walter Unzeitig, Jeremy Hoog, Mark Watson, Olwen Mary Hahn, J. Michael Guenther, Abigail Suzanne Caudle, Travis Dockter, Larissa A. Korde, Anna Weiss, Kelly Hunt, Clifford A. Hudis, Eric P. Winer, Ann H. Partridge, Lisa A. Carey, Matthew James Ellis

JOURNAL OF CLINICAL ONCOLOGY (2020)

Article Oncology

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

Pedram Razavi, Maura N. Dickler, Payal D. Shah, Weiyi Toy, David N. Brown, Helen H. Won, Bob T. Li, Ronglai Shen, Neil Vasan, Shanu Modi, Komal Jhaveri, Betty Ann Caravella, Sujata Patil, Pier Selenica, Stephen Zamora, Aimee M. Cowan, Elizabeth Comen, Andy Singh, Anne Covey, Michael F. Berger, Clifford A. Hudis, Larry Norton, Rebecca J. Nagy, Justin I. Odegaard, Richard B. Lanman, David B. Solit, Mark E. Robson, Mario E. Lacouture, Edi Brogi, Jorge S. Reis-Filho, Mary Ellen Moynahan, Maurizio Scaltriti, Sarat Chandarlapaty

NATURE CANCER (2020)

暂无数据